Recent advances in oxazolidinone antibacterial agent research

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 9, 2004, Pages 1309-1328

  Hutchinson, Douglas K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antibacterial agent; Antibiotic; Efflux pump; Eperezolid; Gram negative; Gram positive; Linezolid; Methicillin resistant Staphylococcus aureus; Methicillin resistant Staphylococcus epidermis; Monoamine oxidase inhibitor; Oxazolidinones; Penicillin resistant streptococci; Protein synthesis inhibitors; Ribosome; Vancomycin resistant Enterococci; Vancomycin resistant Staphylococcus aureus

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMYCOBACTERIAL AGENT; BENZENE DERIVATIVE; CHLORAMPHENICOL; CITALOPRAM; DA 7687; DA 7867; DALFOPRISTIN PLUS QUINUPRISTIN; DECONGESTIVE AGENT; EPEREZOLID; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; OXAZOLIDINONE DERIVATIVE; PNU 100480; PNU 288034; PNU 92300; PNU 94756; RANBEZOLID; RWJ 334181; RWJ 337813; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VRC 4530; VRC 4580;

ANEMIA; ANTIBIOTIC RESISTANCE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFUSION; DIAPHORESIS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; FOOD DRUG INTERACTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; HYPERTHERMIA; MORAXELLA CATARRHALIS; REVIEW; SEROTONIN SYNDROME; STRUCTURE ACTIVITY RELATION; SWEAT GLAND DISEASE; THROMBOCYTOPENIA;

EID: 4544361770     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.9.1309     Document Type: Review

References (66)

1. MOELLERING RC: Past, present, and future of antimicrobial agents. Am. J. Med. (1995) 99(Suppl.6A):11S-18S.
2. GOLD HS, MOELLERING RC: Drug therapy: antimicrobial-drug resistance. N. Engl. J. Med. (1996) 335:1445-1453.
3. HOWARD DH, SCOTT RD, PACKARD R, JONES D: The global impact of drug resistance. Clin. Infect. Dis. (2003) 36(Suppl.1):S4-S10.
4. JONES RN, LOW DE, PFALLER MA: Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Clin. Infect. Dis. (1999) 33:101-112.
5. PFIZER: Zyvox here, Zyvox now: a comprehensive overview. (2003).
6. MOELLERING RC: Linezolid: the first oxazolidinone antimicrobial. Ann. Int. Med. (2003) 138:135-142.
7. LIPSKY BA, ITANI K, NORDEN C, et al.: Treating foot infections in diabetic patients: a randomized, multicenter, opent-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. (2004) 38:17-24.
8. LI Z, WILLIKE RJ, PINTO LA et al.: Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy (2001) 21:263H274.
9. COLCA JR, MCDONALD WG, WALDON DJ et al.: Crosslinking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. (2003) 278:21972-21979.
10. BRICKNER SJ: Oxazolidinone antibacterial agents. Curr. Pharm. Des. (1996) 2:175-194.
11. HUTCHINSON DK: Oxazolidinone antibacterial agents: a critical review. Curr. Topics Med. Chem. (2003) 3:1021-1042.
12. BARBACHYN MR, FORD CW: Oxazolidinone structure-activity relationships leading to linezolid. Angew. Chem. Int. Ed. (2003) 42:2010-2023.
13. RUBINSTEIN E, ISTURIZ R, STANDIFORD HC et al.: Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob. Agents Chemother. (2003) 47:1824-1831.
14. RUBINSTEIN E: Haematological toxicity: the basis and clinical consequences. 43rd ICAAC. Chicago, Il, USA (2003). Abstract 1782.
15. YUNIS AA: Chloramphenicol toxicity: 25 years of research. Am. J. Med. (1989) 87:44N.
16. MARTIN JP, HERBERG JT, SLATTER JG, DEPUIS MJ: Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase A (MAO-A), no clinical evidence of MAO-A inhibition in Phase II or Phase III clinical trials has been observed. 38th ICAAC. San Diego, USA (1998). Abstract A-85.
17. STERNBACH H: The serotonin syndrome. Am. J. Psychiatry (1991) 148:705-713.
18. LEACH TS, LOBECK FG, TODD W, HAFKIN B: lack of serotonin syndrome in Phase III patients receiving linezolid and a selective serotonin re-uptake inhibitor. Proceedings and abstracts of the Infectious Diseases Society of America. (2000). Abstract 64.
19. LAVERY S, HIMABINDU R, MCDANIEL WW, PUSHKIN YR: Linezolid and serotonin syndrome. Psycosomatics (2001) 42:432-434.
20. WIGEN CL, GOETZ MB: Serotonin syndrome and linezolid. Clin. Infect. Dis. (2002) 34:1651-1652.
21. BERNARD L, STERN R, LEW D, HOFFMEYER P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin. Infect. Dis. (2003) 36:1197.
22. NIKAIDO H: Multidrug efflux pumps of Gram-negative bacteria. J. Bacteriol. (1996) 178:5853-5859.
23. MUTNICK AH, ENNE V, JONES RN: Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann. Pharmacother. (2003) 37:769-774.
24. QUINN JP: Resistance in Enterococci and Staphylococci: clinical experience. 43rd ICAAC. Chicago, USA (2003). Abstract F-1783.
25. RIEDL B, ENDERMANN R: Recent developments with oxazolidinone antibacterial agents. Expert Opin. Ther. Patents (1999) 9:625-633.
26. GENIN MJ: Recent progress with oxazolidinone antibacterial agents. Expert Opin. Ther. Patents. (2000) 10:1405-1414.
27. RATTAN A: RBx-7644, ranbezolid hydrochloride. Drugs Fut. (2003) 28:1070-1077.
28. HOELLMAN DB, LIN G, EDNIE LM, RATTAN A, JACOBS MR, APPELBAUM PC: Antipneumococcal and antistaphylococcal activities of ranbezolid (RBx-7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother. (2003) 47:1148-1150.
29. RATTAN A, MEHTA A, DAS B et al.: In vitro activity of RBx 7644, an extended spectrum investigational oxazolidinone. 42nd ICAAC. San Diego, USA (2002). Abstract F-1291.
30. EDNIE LM, RATTAN A, JACOBS MR, APPELBAUM PC: Antianaerobe activity of RBx-7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob. Agents chemother. (2003)47:1143-1147.
31. BARBACHYN MR, HUTCHINSON DK, BRICKNER SJ et al.: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. (1996) 39:680-685.
32. SINGH U, RAJU B, LAM S et al.: New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones. Bioorg. Med. Chem. Lett. (2003) 13:4209-4212.
33. GREENE ML, BARBACHYN MR, JACOBSEN SK et al.: Synthetic studies leading to the identification of PNU-288034, a potent new oxazolidinone antibacterial agent. 42nd ICAAC. San Diego, USA (2002). Abstract F-1333.
34. SCHAADT RD, GREENE ML, SWEENEY MT, et al.: In vitro antibacterial activity of PNU-288034, a novel oxazolidinone antibiotic. 42nd ICAAC. San Diego, USA (2002). Abstract F-1334.
35. HAMEL JC, STAPERT D, MOERMAN JK, CARTER JR, FORD CW: In vivo efficacy evaluation of PNU-288034, an oxazolidinone antibiotic. 42nd ICAAC. San Diego, USA (2002). Abstract F-1339.
36. HUMPHREY WR, SHATTUCK MH, ZIELINSKI RJ, et al.: Pharmacodynamic assessment of the oxazolidinone PNU-288034 against Streptococcus pneumoniae in gerbil models of acute otitis media (AOM). 42nd ICAAC. San Diego, USA. (2002). Abstract F-1343.
37. DAILEY C, BUCHANAN L, PAGANO P et al.: Efficacy of PNU-2888034 in the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. 42nd ICAAC. San Diego, USA. (2002). Abstract F-1340.
38. RENSLO AR, JAISHANKAR P, VENTKATACHALAM R et al. Antimicrobial activity of novel azabicyclo[3.1.0] hexyl phenyloxazolidinones. 43rd ICAAC. Chicago, USA (2003). Abstract F-2100.
39. PADGET S, FOLENO BD, BOGGS CM et al.: Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorg. Med. Chem. Lett. (2003) 13:4173-4177.
40. FOLENO B, GOLDSCHMIDT R, LICATA L et al.: In vitro antibacterial activity of the pyrrolopyridine-substituted oxazolidinones RWJ-334181 and RWJ-337813. 41st ICAAC. Chicago, USA (2001). Abstract F-1049.
41. LEE JS, CHO YS, CHANG MH, KOH HY, CHUNG BY, PAE AN: Synthesis and in vitro activity of novel isoxazolyl tetrahydropyridinyl oxazolidinone antibacterial agents. Bioorg. Med. Chem. Lett. (2003) 13:4117-4120.
42. GRAVESTOCK MB, ACTON D, BETTS M, MCGREGOR A, SHELDON C, SWAIN M et al.: New C-5 side chain structural analogs in the oxazolidinone series: N-linked azolylmethyl groups as replacements for the acetamidomethyl function. 43rd ICAAC. Chicago, USA (2003) Abstract F-2099.
43. GRAVESTOCK MB, ACTON DG, BETTS MJ et al.: New classes of antibacterial oxazolidiones with C-5, methylene O-linked heterocyclic side chains. Bioorg. Med. Chem. Lett. (2003) 13:4179-4186.
44. HAO Y, BARBACHYN MR, GREENE ML, et al.: Synthesis and antibacterial activity of oxazolidinones incorporating C-ring oxetanes and thietanes. 42nd ICAAC. San Diego, USA (2002). Abstract F-1321.
45. BARBACHYN MR, GREGA KC, GENIN MJ et al.: The potentiating effect of remote chirality on the antibacterial activity of a series of 2-substituted indolinyl oxazolidinones. 41st ICAAC. Chicago, USA (2001). Abstract F-1042.
46. CISKE FL, BARBACHYN MR, GENIN MJ et al.: The effect of remote chirality on the antibacterial activity of indolinyl, tetrahydroquinolyl and dihydrobenzoxazinyl oxazolidinones. Bioorg. Med. Chem. Lett. (2003) 13:4235-4239.
47. JOHNSON PD, ARISTOFF PA, ZURENKO GE et al.: Synthesis and biological evaluation of benzazapine oxazolidinone antibacterials. Bioorg. Med. Chem. Lett. (2003) 13:4197-4200.
48. PAGET S, BOGGS C, FOLENO B et al.: Synthesis and antibacterial activity of pyrrolopyrimidine oxazolidinones. 42nd ICAAC. San Diego, USA (2002). Abstract F-1318.
49. YONG D, YUM JH, LEE K, CHONG Y, CHOI SH, RHEE JK: In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. (2004) 48:352-357.
50. LEE TH, KIM DH, CHO JH, CHOI SH, IM WB, RHEE JK: In vivo efficacy of DA-7867, a new oxazolidinone in murine systemic and local infections. 42nd ICAAC. San Diego, USA (2002). Abstract F-1314.
51. WEIDNER-WELLS MA, BOGGS CM, FOLENO BD et al.: Novel piperidinyloxy oxazolidinone antimicrobial agents. Bioorg. Med. Chem. Lett. (2001) 11:1829-1832.
52. WEIDNER-WELLS MA, BOGGS CM, FOLENO BD et al.: Novel piperidinyloxy oxazolidinone antibacterial agents, diversification of the N-substituent. Bioorg. Med. Chem. Lett. (2002) 12:2345-2351.
53. WEIDNER-WELLS MA, BOGGS CM, NELSON EA et al.: Piperidinyloxy substituted oxazolidinones as antibacterial agents. Diversification of the N-substituent. 40th ICAAC. Toronto, Canada. (2000). Abstract F-1828.
54. SCIOTTI RJ, PLIUSHCHEV M, WIEDEMAN PE et al.: The synthesis and biological evaluation of a novel series of anti-microbials of the oxazolidinone class. Bioorg. Med. Chem. Lett. (2002) 12:2121-2123.
55. BARTEL S, ENDERMANN R, GUARNIERI W et al.: Synthesis and biological activity of novel imidazobenzoxazinyl-oxazolidinones. 40th ICAAC. Toronto, Canada (2000) Abstract F-1823.
56. GREGORY WA, BRITTELLI DR, WANG CL et al.: Oxazolidinone antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The 'B' group. J. Med. Chem. (1989) 32:1673-1681.
57. DALY JS, ELIOPOULOS GM, WILLEY S, MOELLERING RC: Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob. Agents Chemother. (1988) 32:1341-1346.
58. THOMASCO LM, GADWOOD RC, WEAVER EA et al.: The synthesis and antibacterial activity of 1,3,4-thiadiazole phenyl oxazolidinone analogs. Bioorg. Med. Chem. Lett. (2003) 13:4193-4196.
59. GRAVESTOCK MB, BETTS MJ, BLACK E et al.: Structural analogs of AZD2563 II: in vitro evaluation of isoxazoline analogs with O- and NH-linked C-5 isoxazole side chains. 42nd ICAAC. San Diego, USA (2002). Abstract F-1302.
60. HUTCHINSON DK, BARBACHYN MR, BRICKNER SJ et al.: Piperazinyl oxazolidinones: structure-activity relationships of a new class of oxazolidinone antibacterial agents. 35th ICAAC. San Francisco, USA (1995) Abstract F-207.
61. BARBACHYN MR, CLEEK GJ, DOLAK LA et al.: Oxazolidinone bioisosteres: studies leading to the identification of phenylisoxazolines as novel and potent antibacterial agents. 39th ICAAC. San Francisco, USA. (1999). Abstract F-572.
62. ALBRECHT HA, BESKID G, CHRISTENSON JG et al.: Dual-action cephalosporins: cephalosporin 3′-quinolone carbamates. J. Med. Chem. (1991) 34:2857-2864.
63. GORDEEV MF, HACKBARTH C, BARBACHYN MR et al.: Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett. (2003) 13:4213-4216.
64. HUBSCHWERLEN C, SPECKLIN JL, BAESCHLIN DK et al.: Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg. Med. Chem. (2003) 11:2313-2319.
65. HUBSCHWERLEN C, SPECKLIN JL, BAESCHLIN DK et al.: Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action. Bioorg. Med. Chem. Lett. (2003) 13:4229-4233.
66. WALSH C: Antibiotics - actions, origins, resistance. ASM Press, Washington, DC, USA (2003).